Tag: e-Rapa

Rapamycin Holdings Treats First Humans in eRapa Clinical Trial
Articles, Featured

Rapamycin Holdings Treats First Humans in eRapa Clinical Trial

Rapamycin Holdings, Inc. (RHI), a privately-held drug development company, has started treating human patients with its proprietary formulation of a ground-breaking cancer prevention drug. The San Antonio-based company is commercializing eRapa, a novel reformulation of the generic drug Rapamycin. This first human Phase 1b clinical trial of eRapa will treat men with early-stage prostate cancer.Twelve to 24 qualified patients are in the first human trials to establish safety and the optimal dose of eRapa. Michael Liss, M.D., a urologic oncologist at UT Health San Antonio MD Anderson Cancer Center, is leading the clinical trial at the center where the Phase 1b study is being conducted. The cancer center has a long history of testing cancer breakthrough therapies in their early-phase cance...
SwRI Shares Pharmaceutical Expertise with New Workshop Oct. 8
Articles, Featured

SwRI Shares Pharmaceutical Expertise with New Workshop Oct. 8

Southwest Research Institute (SwRI) is hosting a one-day workshop on Oct. 8 to teach life science professionals strategies and tools needed for a more successful investigational new drug (IND) submission. This workshop, to be held at SwRI, is designed for beginner- to intermediate-level bioscience professionals involved in new drug development.The workshop will help showcase SwRI’s specialized capabilities such as its new clean room, high-potency laboratory space, and complimentary storage facility to the bioscience community. The institute’s 2017 annual report details recent infrastructure investments and educational outreach efforts such as this inaugural workshop that can help attract more drug development to SwRI as well as benefit local startups bringing drugs to market.The Sm...